Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZEN003694 + binimetinib
- Development stage
- Phase 1
- Lead developer
- Zenith Epigenetics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ZEN003694 + binimetinib is an investigational combination therapy being developed for the treatment of advanced or metastatic solid tumors, specifically those harboring RAS pathway alterations and triple-negative breast cancer (TNBC). ZEN003694 is an oral small molecule inhibitor of the bromodomain and extra-terminal (BET) family of proteins (including BRD2, BRD3, and BRD4), which are epigenetic readers that regulate the transcription of genes involved in cell growth and survival. Binimetinib is an oral, potent, and selective inhibitor of mitogen-activated protein kinase kinase 1 and 2 (MEK1/2), key components of the MAPK/ERK signaling pathway. Preclinical evidence suggests that BET inhibition can sensitize tumors to MEK inhibitors and overcome acquired resistance by suppressing the upregulation of alternative signaling pathways. This combination is currently being evaluated in Phase 1/2 clinical trials sponsored by the National Cancer Institute (NCI) in collaboration with Zenith Epigenetics and Pfizer.
- Other names
- BET Bromodomain Inhibitor ZEN-3694
02
Targets
BRD2 (Bromodomain-containing protein 2)BRD3 (Bromodomain-containing protein 3)BRD4 (Bromodomain-containing protein 4)BRDT (Bromodomain testis-specific protein)MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)MEK2 (Dual specificity mitogen-activated protein kinase kinase 2)
Beyond the preview
Go deeper on ZEN003694 + binimetinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZEN003694 + binimetinib.